Octagam (Human Normal Immunoglobulin)

Octagam is an immunoglobulin therapy that acts on disorders of the immune system.

• Primary immunodeficiency diseases: provides supplemental IgG antibodies to reduce infection frequency.
• Chronic inflammatory demyelinating polyneuropathy (CIDP): helps lessen nerve inflammation and improves muscle strength.
• Multifocal motor neuropathy (MMN): reduces disease activity and supports motor function.
• Immune thrombocytopenia (ITP) refractory to other treatments: raises platelet counts and decreases bleeding risk.
• Kawasaki disease (in children): mitigates inflammatory response and lowers fever and coronary artery complications.

• Octagam contains pooled human IgG antibodies that bind to a broad range of antigens, neutralizing pathogens and modulating immune system activity. The administered immunoglobulin interacts with Fc receptors on immune cells, suppresses inflammatory cytokine release, and provides passive immunity, thereby restoring immune balance in patients with antibody deficiencies or autoimmune-mediated inflammation.

Adverse reactions to Octagam may vary in frequency and severity.

Common Side Effects

• Headache
• Fever
• Chills
• Nausea
• Fatigue
• Mild infusion‑related rash

Serious or Rare Side Effects

• Anaphylaxis
• Acute hemolytic anemia
• Thromboembolic events
• Renal impairment
• Severe aseptic meningitis
• Transfusion‑related acute lung injury (TRALI)

When using Octagam, clinicians should consider several safety measures.

• Pre‑infusion assessment: review patient history for IgA deficiency and prior reactions.
• Infusion rate: start slowly and increase gradually to reduce adverse events.
• Hydration status: ensure adequate fluid intake to support renal function.
• Concomitant immunosuppressants: monitor for enhanced immunosuppression.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Live vaccines: may reduce vaccine efficacy and increase infection risk.
• High‑dose aspirin or anticoagulants: heightened bleeding risk.

Moderate Interactions (Monitor Closely)

• Corticial‑  
• Corticosteroids
• Rituximab
• Immunosuppressive agents
• ACE‑  
• ACE inhibitors